Publications list of KReinikainen_01072015

LIST OF PUBLICATIONS (1-3)
PHARMACEUTICAL EXPERIENCE (4)
Kari J. Reinikainen
MD, PhD, Adjunct Professor of Neurology

Reinikainen KJ: List of publications 2
_________________________________________________________________________________________
1. ORIGINAL PAPERS AND REVIEWS
1.1 Reinikainen K ja Partanen J: Kliinis-neurofysiologiset menetelmät kasvohermohalvauksen ennusteen
arvioinnissa. Suomen Lääkäril 33:2142-2146, 1978
1.2 Soininen H, Reinikainen K ja Riekkinen PJ: Dementian hoitomahdollisuuksista. Sandoz Report 11:6,
p. 3-6, 1980
1.3 Reinikainen K ja Riekkinen P: Hermovälittäjäaineiden osuus Alzheimerin taudin patogeneesissa ja
hoidossa. Duodecim 99:6, 379-387, 1983
1.4 Sivenius J, Keränen T, Reinikainen K ja Riekkinen PJ: Natriumvalproaatti epilepsian hoidossa.
Suomen Lääkäril 38:745-748, 1983
1.5 Keränen T, Reinikainen K, Partanen J, Sivenius J, Yletyinen A ja Riekkinen PJ: Ambulatorisen EEG:n
pitkäaikaisrekisteröinti epilepsian erotusdiagnostiikassa. Suomen Lääkäril 39:1675-1678, 1984
1.6 Herranen J, Huhtikangas A, Tirronen H, Halonen T, Huuskonen M, Reinikainen K and Riekkinen PJ:
Quantification of a number of biogenic amines and their metabolites in brain homogenates by gas
chromatography - mass spectrometry. J Chromatogr 307:241-249, 1984
1.7 Soininen H, Jolkkonen JT, Reinikainen K, Halonen TO and Riekkinen PJ: Reduced cholinesterase
activity and somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with dementia of
the Alzheimer type. J Neurol Sci 63:167-172, 1984
1.8 Reinikainen K, Keränen T, Lehtinen R, Kälviäinen R, Saari T ja Riekkinen P: Pään tietokone-
tomografia ja EEG aikuisiän epilepsian diagnostiikassa. Suomen Lääkäril 39:2753-2757, 1984
1.9 Reinikainen K, Soininen H, Kosma VM, Halonen T, Jolkkonen J and Riekkinen PJ: Neurotransmitters
in senile dementia of Alzheimer type (SDAT) and in vascular dementia. In: Interdiscipl Topics Geront
Vol. 19, pp. 184-197. Ed. P.H. von Hahn (Modern Approaches to the Dementias, Part 1). Karger,
Basel 1985
1.10 Riekkinen PJ, Reinikainen K ja Jolkkonen J: Neuropeptidit hermoston vanhenemis- ja demen-
toitumisprosesseissa. Suomen Lääkäril 41:582-588, 1986
1.11 Reinikainen K, Riekkinen P ja Jolkkonen J: Neuropeptidit aivojen normaalissa vanhenemisessa,
Alzheimerin taudissa ja Parkinsonin taudissa. Sandoz Report 17:23- 26, 1986
1.12 Sirviö J, Reinikainen K, Helkala E-L, Paljärvi L, Soininen H and Riekkinen PJ: Cholinergic deficiency
in the vascular type of dementia. 8th
Scandinavian Congress of Gerontology, Tampere, May 25th
-28th
,
ed. Hervonen A, pp. 101-103, 1986
1.13 Riekkinen PJ, Reinikainen K, Helkala E-L, Soininen H and Sirviö J: Somatostatin in normal aging, in
Alzheimer’s disease and Parkinson’s disease. 8th
Scandinavian Congress of Gerontology, Tampere,
May 25th
-28th
, ed. Hervonen A, pp. 105-108, 1986
1.14 Riekkinen PJ, Soininen H, Reinikainen K, Helkala E-L and Paljärvi L: Cholinergic approach from
CSF to Alzheimer brain. In Cellular and Molecular Basis of Cholinergic Function, pp. 874-881, ed. by
Dowdall MJ and Hawthorne JN, Ellis Horwood Ltd., England and VCH Verlagsgesellschaft, FRG,
1987
1.15 Riekkinen PJ, Soininen H, Sirviö J, Reinikainen K, Helkala E-L and Paljärvi L: Dementia without
cholinergic deficit. Gerontology, 33:268-272, 1987

_________________________________________________________________________________________
1.16 Reinikainen KJ, Keränen T, Lehtinen JM, Kälviäinen R, Saari T and Riekkinen PJ: CT brain scan and
EEG in the diagnosis of adult onset seizures. Epilepsy Res, 1:178- 184, 1987
1.17 Reinikainen K, Riekkinen PJ, Jolkkonen J, Kosma V-M, and Soininen H: Decreased somatostatin-like
immunoreactivity in cerebral cortex and cerebrospinal fluid in Alzheimer’s disease. Brain Res
402:103-108, 1987
1.18 Reinikainen KJ, Keränen T, Halonen T, Komulainen H and Riekkinen PJ: Comparison of oxcar-
bazepine and carbamazepine: a double-blind study. Epilepsy Res 1:284-289, 1987
1.19 Reinikainen K: Hermovälittäjäainemuutokset Alzheimerin taudissa. Sandoz Report, 3:23-26, 1987
1.20 Reinikainen K, Riekkinen PJ, Halonen T and Laakso M: Decreased muscarinic receptor binding in
cerebral cortex and hippocampus in Alzheimer’s disease. Life Sci, 41:453-461, 1987
1.21 Soininen H,Riekkinen PJ,Partanen J,Helkala E-L,Laulumaa V,Jolkkonen J and Reinikainen K:CSF
somatostatin correlates with beta power in spectral EEG and with parietotemporal cognitive
dysfunction in Alzheimer patients. Neurosci Lett,85:131-136, 1988
1.22 Reinikainen K, Riekkinen PJ, Paljärvi L, Soininen H, Helkala E-L, Jolkkonen J and Laakso M:
Cholinergic deficit in Alzheimer’s disease: a study based on CSF and autopsy data, Neurochem Res,
13:135-146, 1988
1.23 Reinikainen K, Paljärvi L, Huuskonen M, Laakso M and Riekkinen P: A post-mortem study of
noradrenergic, seotonergic and GABA-ergic neurons in Alzheimer’s disease. J Neurol Sci 84:101-
116, 1988
1.24 Reinikainen K, Halonen T, Paljärvi L, Malminen O, Laakso M and Riekkinen PJ: Dopaminergic
System and monoamine oxidase-B activity in Alzheimer’s disease. Neurobiol Aging, 9:245-252, 1988
1.25 Danner R, Partanen J, Keränen T, Reinikainen K, Hallikainen E and Riekkinen P: Comparison of the
effects of carbamazepine and oxcarbazepine on peripheral nerve conduction. Epilepsy Res, 2:272-275,
1988
1.26 Reinikainen K: Neurotransmitters in Alzheimer’s Disease. Academic thesis, University of Kuopio,
1988
1.27 Reinikainen K, Laulumaa V, Paljärvi L: Hyperkaleeminen periodinen paralyysi. Duodecim, 104:1625-
1629, 1988
1.28 Reinikainen K, Saksa M, Murros K, Kulju T, Partanen J, Paljärvi L ja Riekkinen PJ: Subakuutti
sklerosoiva panenkefaliitti aikuispotilaalla. Duodecim, 104:1712- 1717, 1988
1.29 Koponen H, Stenbäck U, Mattila E, Reinikainen K, Soininen H and Riekkinen PJ: Cerebrospinal fluid
somatostatin in delirium. Psychol Med, 19:605-609, 1989
1.30 Koponen H, Stenbäck U, Mattila E, Reinikainen K, Soininen H and Riekkinen PJ: Cerebrospinal fluid
beta-endorphin in acute delirium. Biol Psychiatry, 25:938-944, 1989
1.31 Koponen H, Stenbäck U, Mattila E, Soininen H, Reinikainen K and Riekkinen PJ: Delirium in the
elderly: Clinical course during the acute stage and one-year follow- up. Acta Psychiatr Scand, 79:579-
585, 1989

_________________________________________________________________________________________
1.32 Reinikainen KJ, Pitkänen A and Riekkinen PJ: 2’,3’-cyclic nucleotide-3’phosphodiesterase activity in
the post-mortem brains of patients with Alzheimer’s disease. Neurosci Lett, 106:229-232, 1989
1.33 Koponen H, Stenbäck U, Mattila E, Reinikainen K, Soininen H and Riekkinen PJ. CSF beta-
endorphin-like immunoreactivity in delirium. Psychiatry Digest 8:10-11, 1989
1.34 Reinikainen KJ, Riekkinen PJ. Noncholinergic neurotransmitter markers in the CSF of patients with
dementia of Alzheimer type. In: Biological Markers in Dementia of Alzheimer Type. Eds. CJ Fow-
ler, LA Carlson, C-G Gottfries, B Winblad, Smith-Gordon, London, UK, 161-178, 1990
1.35 Koponen H, Reinikainen K, Jolkkonen J, Riekkinen PJ. Somatostatin-like immunoreactivity in the
CSF of patients with dementia associated with alcoholism. Acta Neurol Scand; 82:289-291, 1990
1.36 Koponen H, Reinikainen K, Riekkinen PJ. Cerebrospinal fluid somatostatin in delirium II. Changes
at the acute stage and at one year follow-up. Psychol Med 20:501-505, 1990
1.37 Reinikainen KJ, Koponen H, Jolkkonen J, Riekkinen PJ. Decreased somatostatin-like
immunoreactivity in the cerebrospinal fluid of chronic schizophrenic patients with cognitive impair-
ment. Psychiatry Res 33: 307-312, 1990
1.38 Reinikainen K, Soininen H, Riekkinen PJ. Neurotransmitter changes in Alzheimer’s disease:
Implications to diagnostics and therapy. J Neurosci Res 27: 576- 586, 1990
1.39 Riekkinen P, Riekkinen P Jr, Soininen H, Reinikainen K, Laulumaa V, Partanen VSJ, Halonen T,
Paljärvi L. Regulation of EEG delta activity by the cholinergic nucleus basalis. In: Key Topics in
Brain Research. Alzheimer’s disease, Epidemiology, Neuropathology, Neurochemistry and Clinics.
Eds. K Maurer, P Riederer, H Beckmann, Springer-Verlag, Wien, New York, 437-445, 1990.
1.40 Henriksson T, Barbour R, Braa S, Ward P, Fritz L, Johnson-Wood K, Burke W, Reinikainen K,
Riekkinen P and Schenk DB. Analysis and quantitation of the B-amyloid precursor protein in the
cerebrospinal fluid of Alzheimer’s disease patients with a monoclonal antibody, J Neurochem 56:
1037-1042, 1991
1.41 Hartikainen P, Soininen H, Reinikainen KJ, Sirviö J, Soikkeli R and Riekkinen PJ. Neurotransmitter
markers in the cerebrospinal fluid of normal subjects: Effects of aging and other confounding factors. J
Neural Transm 84: 103-117, 1991
1.42 Reinikainen KJ, Soininen H, Paljärvi L and Riekkinen PJ. Neurotransmitter markers in the
cerebrospinal fluid of patients with histologically verfied Alzheimer’s disease. In Alzheimer’s Disease:
Basic Mechanisms, Diagnosis and Therapeutic Strategies. Eds. Iqbal K, McLachlan DRC, Winblad B
and Wisniewski HM, John Wiley & Sons Ltd, 525-532, 1991
1.43 Alhainen K, K, Riekkinen P Sr, Helkala E-L, Partanen J, Laulumaa V, Reinikainen K, Soininen H amd
Airaksinen M. The effect of THA on cognitive functions and spectral power EEG in Alzheimer’s
disease: Preliminary results of an open study. In Alzheimer’s Disease: Basic Mechanisms, Diagnosis
and Therapeutic Strategies. Eds. Iqbal K, McLachlan DRC, Winblad B and Wisniewski HM, John
Wiley & Sons Ltd, 611-619, 1991
1.44 Airaksinen MS, Paetau A, Paljärvi L, Reinikainen K, Riekkinen P, Suomalainen R and Panula P.
Histamine neurons in human hypothalamus: Anatomy in normal and Alzheimer diseased brains.
Neuroscience 44: 465-481, 1991
1.45 Alhainen K, Partanen J, Reinikainen K, Laulumaa V, Soininen H, Airaksinen M and Riekkinen P Sr,
Discrimination of tetrahydroaminoacridine responders by a single dose pharmaco-EEG in Alzheimer’s
disease. Neurosci Lett, 127: 113-116, 1991

_________________________________________________________________________________________
1.46 Koponen H, Sirviö J, Reinikainen KJ and Riekkinen PJ. A longitudinal study of cerebrospinal fluid
acetylcholinesterase in delirium: Changes at the acute stage and and at one year follow-up. Psychiatry
Res 38: 135-142, 1991
1.47 Airaksinen MS, Reinikainen K, Riekkinen P, Panula P. Neurofibrillary tangles and histamine-
containing neurons in Alzheimer hypothalamus. Agents Actions. 33 (1-2); 104-107, 1991
1.48 Alhainen K, Sirviö J, Helkala E-L, Reinikainen K and Riekkinen PJ Sr. Somatostatin and cognitive
functions in Alzheimer’s disease the relationship of cerebrospinal fluid somatostatin increase with
clinical response to tetrahydroaminoacridine. Neurosci Lett, 130: 46-48, 1991
1.49 Nousiainen U, Sainio K, Koponen H, Partanen J, Reinikainen K, Suomalainen T, Tuunainen A,
Mervaala E. Status epileptikus päivystystilanteen ongelma. Duodecim 107: 1648-1652, 1991
1.50 Alhainen KJ, Riekkinen PJ Jr, Soininen HS, Reinikainen KJ, Riekkinen PJ Sr. Responders and
nonresponders in experimental therapy of Alzheimer’s disease. In: Cholinergic basis for Alzheimer
therapy , Eds Becker R, Giacobini E, Birkhauser, Boston, 231-237, 1991
1.51 Hartikainen P, Reinikainen K, Soininen H, Sirviö J, Soikkeli R and Riekkinen PJ. Neurochemical
markers in the cerebrospinal fluid of patients with Alzheimer’s disease, Parkinson’s disease and
amyotrophic lateral sclerosis. J Neural Transm 4: 53-68, 1992
1.52 Soininen H, Reinikainen K, Partanen J, Mervaala E, Paljärvi L, Helkala EL, Riekkinen P Sr. Slowing
of the dominant occipital rhythm in electroencephalogram is associated with low concentration of
noradrenaline in the thalamus in patients with Alzheimer’s disease. Neurosci Lett 137: 5-9, 1992
1.53 Alhainen K, Reinikainen K, Riekkinen P. Alzheimerin taudin kolinerginen lääkehoito. Sandoz Report
23: 11-14, 1992
1.54 Alhainen K, Riekkinen P Sr, Helkala E-L, Partanen J, Laulumaa V, Reinikainen K, Soininen H and
Airaksinen M. The effect of THA on cognitive functions and spectral power EEG in Alzheimer’s
disease: Preliminary results of an open study. Neurosci Lett, in press
1.55 Koivisto K, Helkala E-L, Reinikainen KJ, Hänninen T, Mykkänen L, Laakso M, Pyörälä K and
Riekkinen PJ. Population based dementia screening program in Kuopio: The effect of education, age
and sex on brief neuropsychological tests. J Geriat Psychiatry Neurol 5: 162-171, 1992
1.56 Soininen H, Reinikainen KJ, Partanen J, Helkala E-L, Paljärvi L and Riekkinen PJ. Slowing of
electroenchephalogram and choline acetyltransferase activity in post-mortem frontal cortex in definite
Alzheimer’s disease, Neuroscience 49: 529-535, 1992
1.57 Alhainen K, Helkala E-L, Reinikainen K, Riekkinen P Sr. The relationship of cerebrospinal fluid
monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer’s
disease. J Neural Transm 5: 185-192, 1993
1.58 Dahlöf C, Björkman R (For The Finnish-Swedish Oral Diclofenac-K Study Group: Kilpeläinen H,
Koivisto K, Murros K, Reinikainen K, Saksa M, Andersson P). Diclofenac-K (50 and 100 mg) andf
placebo in the acute treatment of migraine. Cephalalgia 13: 117-123, 1993
1.59 Keränen T, Reinikainen KJ. Okskarpatsepiini - uusi ensisijaislääke epilepsian hoitoon. Suomen
Lääkärilehti, 48: 3229-3235, 1993
1.60 Soininen H, Reinikainen KJ, Puranen M, Helkala E-L, Paljärvi L and Riekkinen PJ. Wide third
ventricle correlates with low choline acetyltransferase activity of the neocortex in Alzheimer patients.
Alzheimer Dis Assoc Disord, 7: 39-47, 1993

_________________________________________________________________________________________
1.61 Hänninen T, Reinikainen KJ, Helkala EL, Koivisto K, Riekkinen PJ. Subjective memory complaints
and personality traits in normal aged subjects. J Am Ger Soc 42: 1-4, 1994
1.61 Koivisto K, Reinikainen KJ, Hänninen T, Helkala EL, Mykkänen L, Laakso M, Pyörälä K, Riekkinen
PJ. The prevalence of age-associated memory impairment in elderly subjects. Neurology 45: 741-747,
1995
1.62 Reinikainen K ja Scheinin M. Alzheimerin taudin lääkehoito, 492-496. Kirjassa Lääketieteellinen
farmakologia ja toksikologia, toim. Pelkonen O ja Ruskoaho H. Kustannus Oy Duodecim, Helsinki,
1995
1.63 Hänninen T, Hallikainen M, Koivisto K, Helkala E-L, Reinikainen KJ, Soininen H, Mykkänen L,
Laakso M, Pyörälä K, Riekkinen PJ. A follow-up study of age-associated memory impairment:
neuropsychological predictors of dementia. J Am Geriatr Soc 43: 1007- 1015, 1995
1.64 Hänninen T, Koivisto K, Reinikainen KJ, Helkala E-L, Soininen H, Mykkänen L, Laakso M,
Riekkinen PJ. Prevalence of ageing-associated cognitive decline in an elderly population. Age and
Ageing, 25: 201-205, 1996
1.65 Koivisto K, Reinikainen KJ, Hänninen T. Reply from the authors (Letter to the Editor related to paper
1.61). Neurology 46: 1490-1491, 1996
1.66 Torpström A, Tulla H, Niskanen L, Reinikainen K. Kateenkorvan poiston vaikutus myastenia
gravikseen. Myastenia-viesti 3; 5- 11, 1996
1.67 Suomen muistitutkimusyksiköiden asiantuntijaryhmä (Erkinjuntti T, Alhainen K, Frey H, Helkala E-L,
Hervonen A, Hietanen M, Juva K, Kivelä S-L, Koponen H, Koivisto K, Majamaa K, Myllylä V,
Pirttilä T, Reinikainen KJ, Riekkinen P Jr, Rinne J, Saarela T, Soininen H, Viramo P). Muistihäiriöt
ja dementia. Suomen Lääkärilehti 51; 2949-2957, 1996
1.68 Reinikainen K. Neurofarmakologia ja dementia, sivut 347-354. Kirjassa Mieli Ja Aivot -
Kognitiivinen neurotiede (ISBN 951-29-0852-2), toim. Revonsuo, Lang, Aaltonen, Painosalama Oy,
Turku, 1996
1.69 Torpström A, Tulla H, Niskanen L, Reinikainen K. Tymektomian merkitys myastenia graviksen
hoidossa. Suomen Lääkärilehti, 52 (10); 1115-1119, 1997
1.70 Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R, Mäki-Ikola O, Reinikainen K and
Scheinin M. Lack of adverse interactions between concomitantly administered selegiline and
citalopram. Clinical Neuropharmacology, 20; 419-433, 1997
1.71 Pirttilä T, Koivisto K, Mehta PD, Reinikainen K, Kim KS, Kilkku O, Heinonen E, Soininen H,
Riekkinen P Sr and Wisniewski HM. Longitudinal study of cerebrospinal fluid amyloid proteins and
apolipoprotein E in patients with probable Alzheimer’s disease. Neurosci Letters, 249; 21-24, 1998
farmakologia ja toksikologia, 2.uudistettu painos, toim. Pelkonen O ja Ruskoaho H. Kustannus Oy
Duodecim, Helsinki, 1999
1.73 Rouru J, Gordin A, Huupponen R, Huhtala S, Savontaus E, Korpela K, Reinikainen K, Scheinin M.
Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa
disposition. Eur J Clin Pharmacol, 55; 461-467, 1999

_________________________________________________________________________________________
1.74 Alafusoff I, Helisalmi S, Heinonen EH, Reinikainen K, Hallikainen M, Soininen H, Koivisto K.
Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer’s
disease. Eur J Clin Pharmacol, 55; 815-819, 2000
1.75 Myllylä V, Kultalahti E-R, Haapaniemi H, Leinonen M and the FILOMEN Study group (KR in Study
Group, Head of the Parkinson Project by the Sponsor): Twelve-Month safety of entacapone in patients
with Parkinson’s Disease. Eur J Neurology 8: 53-60, 2001
1.76 Sivenius J, Sarasoja T, Aaltonen H, Heinonen E, Kilkku O, Reinikainen K. Selegiline treatment
facilitates recovery after stroke. Neurorehabilitation and Neural Repair. 15: 183-190, 2001
1.77 Poewe W, Deuschl G, Gordin A, Kultalahti E-R, Leinonen M, and the Celomen Study Group (KR in
the Study Group, Head of the Parkinson Project by the Sponsor). Efficacy and safety of entacapone in
Parkinson’s Disease patients with suboptimal Levodopa response: a 6-month randomized placebo-
controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand, 105;
245-255 , 2002
1.78 Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S and Reinikainen K. Entacapone
improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of
L-dopa/carbidopa dose. Br J Clin Pharmacol, 54; (4): 363-371, 2002
1.79 Remes AM, Liimatta EV, Winqvist S, Tolonen U, Ranua AJ, Reinikainen K, Hassinen IE; Majamaa
K. Ubiquinone and nicotinamide treatment of patients with 3243A-> G mtDNA mutation. Neurology
59: 1275-1277, 2002
1.80 Beck S, Hubble J, Reinikainen K. Rebuttal letter. Mov Disorders, 17: 1397-1399, 2002
1.81 Larsen JP; Worm-Petersen J, Siden Å, Gordin A, Reinikainen K, Leinonen M and the NOMASAFE
study group. The tolerability and efficacy of entacapone over 3 years in patients with Parkinson’s
disease. European Journal of Neurology, 10: 137-146, 2003
1.82 Brooks DJ, Sagar H, and the UK-Irish Entacapone Study Group (KR in the Study Group, Head of the
Parkinson Project by the Sponsor). Entacapone is beneficial in both fluctuating and non-fluctuating
patients with Parkinson’s disease. A randomized, placebo-controlled, double-blind six-month study. J
Neurol, Neurosurg and Psychiatry 74: 1071-1079, 2003
farmakologia ja toksikologia, 3.uudistettu painos, toim. Pelkonen O ja Ruskoaho H. Kustannus Oy
Duodecim, Helsinki, 2003
1.84 Reichmann H, Boas J, Mac Mahon D, Myllylä V, Hakala A, Reinikainen K on behalf of the
COMQOL study group. Efficacy of combining levodopa with entacapone on quality of life and
activities of daily living in patients experiencing wearing – off type motor fluctuations. Acta Neurol
Scand 2005; 111: 21-28
1.85 Paija O, Laine K, Kultalahti E-R, Leinonen M, Huupponen R, Gordin A and Reinikainen K.
Entacapone Increases Levodopa Exposure and Reduces Plasma Levodopa Variability When Used
With Sinemet CR. Clin Neuropharmacol 2005; 28: 115-119

_________________________________________________________________________________________
2. CONGRESS ABSTRACTS
2.1 Reinikainen K, Keränen T and Riekkinen PJ: Efficacy and side-effects of clonazepam in long-term
treatment in institutionalized patients with epilepsy. 5th
Scandina- vian Epilepsy Congress, June 10.-
13., Siilinjärvi Rehabilitation Center, 1981
2.2 Keränen T, Reinikainen T, Laulumaa V, Koskela K, Hallikainen E and Riekkinen PJ: Carbamazepine
monotherapy versus polytherapy in chronic epilepsies. 24th
Scandinavian Neurology Congress,
Copenhagen, Denmark, June 9.-12., 1982. Acta Neurol Scand, (Suppl 90) 65:190, 1982
2.3 Keränen T, Reinikainen K, Lehtinen J, Saari T and Riekkinen PJ: Correlations of CT and EEG
findings in patients with recently diagnosed epilepsy. 24th
Scandinavian Neurology Congress,
Copenhagen, Denmark, June 9.- 12., 1982. Acta Neurol Scand, (Suppl 90) 65:208-209, 1982
2.4 Reinikainen K, Soininen H, Kosma V.-M, Halonen T, Pitkänen A and Riekkinen PJ:
Neurotransmitters-related enzymes (ChAT, AChE, GAD, MAO-A, MAO-B) in senile dementia of the
Alzheimer type and in vascular dementia. Fourth meeting of the European Society of Neurochemistry,
12.-18.9.1982, Catania, Italy. In: Basic and clinical aspects of Molecular Neurobiology, p. 521. Eds.
A.M.G. Stella et al., Fondazione Menarini, Milano, Italy 1982
2.5 Soininen H, Pitkänen A, Halonen T, Reinikainen K and Riekkinen PJ: Acetylcholinesterase and
dopamine-beta -hydroxylase activities in CSF of patients with senile dementia of Alzheimer type.
Fourth meeting of the European Society for Neurochemistry, 12.-18.9.1982, Catania, Italy. In: Basic
and clinical aspects of Molecular Neurobiology, p. 522. Eds. A.M.G. Stella et al., Fondazione
Menarini, Milano, Italy 1982
2.6 Reinikainen K, Soininen H, Kosma V.-M, Halonen T, Pitkänen A and Riekkinen PJ:
Neurotransmitter-related enzymes in senile dementia of the Alzheimer type (SDAT) and in vascular
dementia. Second National Meeting of Neurochemistry, June 28-29, 1982, Publications of the
University of Kuopio, 3/82, Abstracts ed. by Halonen T, p. 21, 1982
2.7 Soininen H, Pitkänen A, Halonen T, Reinikainen K and Riekkinen PJ: Acetylcholinesterase and
dopamine-beta- hydroxylase activities in CSF of patients with senile dementia of Alzheimer type.
Second National Meeting of Neurochemistry, June 28-29, 1982, Publications of the University of
Kuopio, 3/82, Abstracts ed. by Halonen T, p. 21, 1982
2.8 Pitkänen A, Reinikainen K, Halonen T, Kilpeläinen H, and Riekkinen PJ: A fluorometric method for
assay of 2’, 3’-cyclic nucleotide 3’-phosphodiesterase enzyme activity in dementia. Second National
Meeting of the Neurochemistry, June 28-29, 1982, Publications of the University of Kuopio, 3/82,
Abstracts ed. by Halonen T, p. 33, 1982
2.9 Reinikainen K, Keränen T, Hallikainen E, Riekkinen PJ: Substitution of diphenylhydantoin therapy by
oxcarbazepine or carbamazepine: A double-blind study. Scientific Presentation Application 15th
Epilepsy International Symposium and American Epilepsy Society Meeting, September 26-30, s. 448,
1983
2.10 Partanen J.V, Danner R, Reinikainen K, Keränen T and Riekkinen PJ: The comparison of
carbamazepine and oxcarbazepine treatment with neurophysiological variables. Scientific Presentation
Application 15th
Epilepsy International Symposium and American Epilepsy Society Meeting,
September 26-30, s. 452, 1983
2.11 Riekkinen P, Jolkkonen J, Reinikainen K, Soininen H and Vornanen M: Somatostatin and Alzheimer’s
disease. Peptides and Neurological disease. 7.-10.8.1983, Robinson College, Cambridge.
2.12 Keränen T, Reinikainen K and Riekkinen PJ: Carbamazepine monotherapy versus polytherapy in
chronic epilepsies. The 25th
Scandinavian Congress of Neurology, Bergen, Norway, 13.-16.6.1984.
Acta Neurol Sand, (Suppl 98) 69:87-88, 1984

_________________________________________________________________________________________
2.13 Reinikainen K, Keränen T, Hallikainen E, Riekkinen PJ: Substitution of diphenylhydantoin by
oxcarbazepine or carbamazepine: double-blind study. The 25th
Scandinavian Congress of Neurology,
Bergen, Norway, 13.- 16.6.1984, Acta Neurol Scand, (Suppl 98) 69:89-90, 1984
2.14 Hallikainen E, Danner R, Partanen V.J, Keränen T, Reinikainen K, Riekkinen PJ: The effects of
carbamazepine and oxcarbazepine on EEG and nerve conduction variables. The 25th
Scandinavian
Congress of Neurology, Bergen, Norway, 13.-16.6.1984. Acta Neurol Scand, (Suppl 98) 69:93-94,
1984
2.15 Sivenius J, Keränen T, Reinikainen K, Yletyinen I, Partanen J, Riekkinen P: Diagnostic evaluation of
ambulatory cassette EEG monitoring in 100 epileptic patients. The 25th
Scandinavian Congress of
Neurology, Bergen, Norway, 13.-16.6.1984. Acta Neurol Scand, (Suppl 98) 69:99-100, 1984
2.16 Soininen H, Koskinen T, Helkala E-L, Partanen J, Reinikainen K and Riekkinen PJ: Synthetic ACTH
4-9 (ORG 2766) in treatment of Alzheimer’s disease. The 25th
Bergen, Norway, 13.-16.6.1984. Acta Neurol Scand, (Suppl 98) 69:236237, 1984
2.17 Reinikainen K, Soininen H, Halonen T and Riekkinen PJ: Cholinergic and monoaminergic neurons in
SDAT and in vascular dementia. The 25th
Scandinavian Congress of Neurology, Bergen, Norway, 13.-
16.1984. Acta Neurol Scand, (Suppl 98) 69:244-245, 1984 (Suppl 98) 69:244- 245, 1984
2.18 Reinikainen KJ, Riekkinen PJ and Jolkkonen JT: Parallel decrease of somatostatin-like
immunoreactivity in the cortical areas and cerebrospinal fluid from patients with Alzheimer’s disease.
XIIIth World Congress of Neurology, Hamburg, 1.-6.9.1985. J Neurol Zeitsch Neurol, (Suppl 232) p.
94, 1985
2.19 Reinikainen KJ, Jolkkonen J, Riekkinen P: Serum prolactin, growth hormone and beta-endorphin
levels after epileptic seizures. 16th
Epilepsy International Congress, Hamburg, September 6-9, 1985
2.20 Reinikainen KJ, Keränen T, Hallikainen E, Riekkinen PJ: Substitution of phenytoin by oxcarbazepine
or carbamazepine: a double-blind study. 16th
Epilepsy International Congress, Hamburg, September 6-
9, 1985
2.21 Riekkinen PJ, Reinikainen K, Halonen T, Soininen H: Cholinergic innervation compared in
Alzheimer’s disease and vascular type of dementia. II International Congress on Psychogeriatric
Medicine, Umeå, Sweden, August 28-31, 1985. Abstract book pp. 49-50
2.22 Reinikainen K, Riekkinen PJ: Reduced somatostatin-like immunoreactivity in the cortex and
cerebrospinal fluid of patients with Alzheimer’s disease. II International Congress on Psychogeriatric
Medicine, Umeå, Sweden, August 28-31, 1985. Abstract book p. 50
2.23 Halonen T, Reinikainen K, Jolkkonen J, Pitkänen A, Kosma V-M and Riekkinen PJ: Neurotransmitter
related enzymes and somatostatin-like immunoreactivity in Alzheimer’s disease (AD) and in vascular
dementia. Tenth Meeting of the International Society for Neurochemistry. Riva del Garda, Italy, May
19-24, 1985. J of Neurochem 44, Suppl. S191 B, 1985
2.24 Sivenius J, Ylinen A, Matilainen R, Reinikainen K and Riekkinen P: Double-blind dose reduction
study in complex partial epilepsy with Vigabatrin - an interim report. The annual meeting of the
American Epilepsy Society, December 3-4, 1985. New York, USA. Epilepsia 26:5, 1985
2.25 Reinikainen KJ, Jolkkonen JT, Ylinen AMA and Riekkinen PJ: Serum prolactin and beta-endorphin
levels after epileptic and pseudoseizures. The annual meeting of the American Epilepsy Society.
December 3-4, 1985.New York, USA. Epilepsia 26:5, 1985
2.26 Riekkinen PJ, Reinikainen K, Jolkkonen J and Soininen H: Somatostatin and somatostatin receptors in
normal aging, Alzheimer’s and Parkinson’s disease. Abstract, The 26th
Scandinavian Congress of
Neurology, Uppsala, June 11-14, 1986. J Med Sci, Suppl. 43, p. 42
2.27 Riekkinen PJ, Reinikainen K, Halonen T and Soininen H: Cholinergic innervation compared in
Alzheimer’s disease and vascular type of dementia. 8. Nordiska kongressen i gerontologi, Tampere
25.-28.5.1986. Kongressikirja s. 52

_________________________________________________________________________________________
2.28 Riekkinen PJ, Soininen H, Partanen J, Helkala E-L, Reinikainen K: Value of clinical and
neuropsychological evaluation, quantitative EEG and CSF examined in follow-up of Alzheimer
patients. 8. Nordiska kongressen i gerontologi, Tampere, 25.-28.5.1986. Kongressikirja s. 53
2.29 Riekkinen PJ, Reinikainen K, Jolkkonen J and Soininen H: Somatostatin and somatostatin receptors in
normal aging, Alzheimer’s and Parkinson’s disease. 8. Nordiska kongressen i gerontologi. Tampere,
25.-28.5.1986. Kongressi-kirja s. 54
2.30 Reinikainen K, Paljärvi L, Riekkinen P.: Dopamine and homovanillic acid concentrations and
monoamine oxidase- B activities in the brain tissue of patients with Alzheimer’s disease. International
Symposium on Alzheimer’s disease, Amsterdam, The Netherlands, May 7-9, 1987. Clinical Neurology
and Neurosurgery, 89-2 (suppl 2): 18-19, 1987
2.31 Soininen H, Riekkinen PJ, Helkala E-L, Laakso M, Laulumaa V, Jolkkonen J and Reinikainen K:
Progression of cortical and subcortical symptoms in Alzheimer’s disease; the relationship to
somatostatin, cholinergic, beta-endorphin and noradrenergic innervation deficiencies. 39th
Annual
meeting, American Academy of Neurology, April 5-11, 1987, New York. Neurology, 37 (suppl
1):226, 1987
2.32 Riekkinen PJ, Sirviö J, Helkala E-L, Soininen H, Reinikainen K, Rinne JK, Rinne UK and Paljärvi L:
Cholinergic markers as indicators of cognitive failure in Alzheimer’s disease and Parkinson’s disease.
International symposium on “Brain acetylcholine: from preclinical to clinical investigations - Clinical
correlates of cerebral cholinergic mechanisms”, Taormina-Messina (Italy), September 22-25, 1987.
Abstraktikirja, s. 102
2.33 Reinikainen KJ, Halonen T, Riekkinen PJ: Comparison of age correlations of cholinergic markers to
other neurotransmitters in aging human brain. 40th
AAN Meeting, April 17-24, 1988, Cincinnati, USA,
Neurology 38 (suppl 1), 287-288, 1988
2.34 Riekkinen PJ, Butters N, Helkala E, Laulumaa V, Soininen H and Reinikainen K: Noradrenergic
Deficiencies in Alzheimer’s Disease. 40th
AAN Meeting, April 17-24, 1988, Cincinnati, USA.,
Neurology 38 (suppl 1), 325, 1988
2.35 Reinikainen KJ, Soininen H, Paljärvi L, Halonen T, Jolkkonen J, Helkala E-L, Laakso M and
Riekkinen PJ: Post-mortem and CSF studies on neurotransmitters in Alzheimer’s disease. International
Symposium on Alzheimer’s Disease, 12-15 June, 1988, Kuopio, Finland. Proceedings of the
Symposium, p 124, 1988
2.36 Koponen H, Stenbäck U, Mattila E, Reinikainen K and Riekkinen PJ: Cerebrospinal fluid somatostatin
in acute confusion. International Symposium on Alzheimer’s Disease, 12-15 June, 1988, Kuopio,
Finland. Proceedings of the Symposium, p 94, 1988
2.37 Reinikainen KJ, Paljärvi L, Soininen H, Halonen T, Jolkkonen J and Riekkinen PJ: Neurotransmitter
changes in Alzheimer’s disease: a post-mortem study. The 27th
15-18 June, 1988, Kuopio, Finland. Acta Neurol Scand, 77 (Suppl 116):127, 1988
2.38 Reinikainen KJ, Pitkänen A and Riekkinen PJ: 2’,3’- cyclic nucleotide-3’-phosphodiesterase activity
in the post-mortem brain tissue in Alzheimer’s disease. 41 AAN Meeting, Chicago, 13-19 April, 1989.
Neurology 39(3), (Suppl 1):194, 1989
2.39 Riekkinen PJ,Sr., Riekkinen PJ, Jr, Soininen H, Reinikainen KJ, Laulumaa V, Partanen VSJ and
Paljärvi L: Regulation of EEG delta activity by the cholinergic nucleus basalis - new evidence. 41
AAN Meeting, Chicago, 13-19 April, 1989. Neurology 39(3), (Suppl 1):170, 1989
2.40 Reinikainen KJ, Halonen T and Riekkinen PJ: Monoamine- oxidase-B and beta-glucuronidase
activities as index of glia in the post-mortem brains of patients with Alzhei- mer’s disease. Aging of
the Brain and Dementia: Ten Years Later, 31 May - 3 June, 1989, Florence, Abstract book, p. 97,
1989
2.41 Koponen H, Reinikainen KJ, Jolkkonen J, Riekkinen PJ: Somatostatin-like immunoreactivity in the
cerebrospinal fluid of chronic alcoholics with cognitive impairment. V Finnish-Soviet symposium on
neuropharmacology and biological alcohol research. 14.-16.9.1989. Publications of the University of

_________________________________________________________________________________________
Kuopio, Medicine, Statistics and Reviews 3/23, 1989
2.42 Riekkinen PJ, Reinikainen KJ, Paljärvi L, Soininen H, Halonen T and Jolkkonen J: Neurotransmitter
changes in Alzheimer’s disease: A post-mortem study. Abstracts of XIVth Word Congress of
Neurology, October 22-27, 1989. Neurology India 37 (Suppl): 80, 1989
2.43 Riekkinen PJ, Hartikainen P, Helkala E-L, Soikkeli R, Reinikainen K and Laulumaa V: Behavioral
and electrophysiological markers of normal and pathological aging. Abstracts of the 12th
Annual
Meeting of European Neuroscience Association, 3-7th
September, Turin 1989. Eur J Neurosci, Suppl
2: 280, 1989
2.44 Airaksinen MS, Paetau A, Paljärvi L, Reinikainen K, Riekkinen P, Panula P. Histaminergic neu-
rons in human tuberomammillary nucleus: Normal anatomy and changes in Alzheimer’s disease.
Abstracts of the 20th
Annual Meeting of the Society for Neuroscience, St. Louis, Missouri 28.10-
2.11.1990:573.
2.45 Alhainen K, Helkala E-L, Partanen VJ, Reinikainen KJ, Laulumaa V, Riekkinen PJ. Preliminary re-
sults of an open trial of THA in Alzheimer’s disease. Proceedings of the 28th
Scandinavian
Congress of Neurology, Reykjavik 6.-9.6.1990. Acta Neurol Scand 128: H82:36, 1990
2.46 Helkala E, Laulumaa V, Soininen H, Reinikainen K, Riekkinen P. Progression of episodic memory
dysfunction in patients with Alzheimer’s disease and controls in the follow-up studies of two years.
Program of the III. International Brain Workshop: Neurodevelopment, Aging and Cognition,
Dubrovnik, 8.- 12.5.1990: 19.
2.47 Helkala E, Laulumaa V, Soininen H, Reinikainen K, Riekkinen P. Progression of episodic memory
dysfunction in patients with Alzheimer’s disease and controls in the follow-up of two years. Abst-
racts of the 13th
Annual Meeting of the European Neuroscience Association, Stockholm, Eur J Ne-
urosci Suppl 3:14. 1990
2.48 Koivisto K, Helkala E-L, Reinikainen K, Hänninen T, Mykkänen L, Laakso M, Pyörälä K,
Riekkinen PJ. Population-based dementia screening in Kuopio: the effect of education on neurop-
sychological tests. 42nd
Annual American Academy of Neurology Meeting, Miami Beach, 30.4.-
6.5.1990. Neurology 40: Suppl 1; 448, 1990
2.49 Reinikainen KJ, Koivisto K, Mykkänen L, Hänninen T, Laakso M, Pyörälä K, Riekkinen PJ. Age-
associated memory impairment in aged population: an epidemiological study. 42nd
Annual American
Academy of Neurology Meeting, Miami Beach, 30.4.-6.5.1990. Neurology 40: Suppl 1; 177, 1990
2.50 Reinikainen KJ, Soininen H, Paljärvi L, Riekkinen PJ. Neurotransmitter markers in the cerebrospinal
fluid of patients with histologically verified Alzheimer’s disease. Abstracts of the Second Interna-
tional Conference on Alzheimer’s Disease and Related Disorders, Toronto, 15.-20.7.1990.
Neurobiol Aging 11:331-332, 1990
2.51 Riekkinen PJ, Alhainen K, Partanen VJ, Reinikainen KJ, Laulumaa V. Evaluation of MU rhythm in
Alzheimer’s disease. Abstracts of the Second International Conference on Alzheimer’s Disease and
Related Disorders, Toronto, 15.-20.7.1990. Neurobiol Aging 11:331- 343, 1990
2.52 Hartikainen P, Helkala EL, Reinikainen K, Sirviö J, Soininen H, Riekkinen PJ. CSF neurochemical
markers in ALS patients. Proceedings of 5th
Nordic Neuroscience Meeting, Kuopio, 12.-15.6.1991:
182.
2.53 Reinikainen K, Koponen H, Jolkkonen J, Riekkinen PJ. Somatostatin-like immunoreactivity is reduced
in the cerebrospinal fluid of chronic alcoholics and schizophrenics with cognitive impairment. 43rd
Annual American Academy of Neurology Meeting, Boston 21.-27.4.1991. Neurology 41; (Suppl 1):
119, 1991
2.54 Reinikainen KJ, Koponen H, Jolkkonen J, Riekkinen PJ. Somatostatinergic neurons are affected in
chronic alcoholics and schizophrenics with cognitive impairment. Proceedings of 5th
Nordic
Neuroscience Meeting, Kuopio, June 12.-15.6.1991:47.

_________________________________________________________________________________________
2.55 Soininen H, Partanen J, Helkala EL, Laulumaa V, Reinikainen K, Riekkinen PJ. Cholinergic system
and EEG: Human studies. Proceedings of 5th
Nordic Neuroscience Meeting, Kuopio, June 12-
15.6.1991: 40.
2.56 Mervaala E, Alhainen K, Partanen J, Jousmäki V, Soininen H, Reinikainen K, Heinonen E, Riekkinen
P. Atipamezole enhances selective attention in event related potentials. Abstracts of PanEuropean
Society of Neurology, Second Congress, Vienna 7-12-12.1991, p 70, 1991
2.57 Reinikainen KJ, Hänninen TJ, Helkala EL, Koivisto KJ, Riekkinen PJ. Prevalence of age-associated
memory impairment in elderly subjects. Abstracts of PanEuropean Society of Neurology, Second
Congress, Vienna 7-12-12.1991, p 106, 1991
2.58 Hänninen TJ, Reinikainen KJ, Helkala EL, Koivisto KJ, Mykkänen LA, Laakso MHS; Pyörälä KP,
Riekkinen PJ. The relationship of memory complaints and some personality traits in normal elderly
subjects. Abstracts of PanEuropean Society of Neurology, Second Congress, Vienna 7-12-12.1991,
109, 1991
2.59 Soininen H, Reinikainen K, Partanen J, Puranen M, Riekkinen PJ. Low frontal choline
acetyltransferase activity is associated with slowing of the EEG and widening of the third ventricle in
Alzheimer’s disease. Abstracts of Society for Neuroscience 21st
Annual Meeting, New Orleans, 10-
15.11.1991, 1448, 1991
2.60 Hänninen T, Reinikainen K, Helkala EL, Koivisto K, Mykkänen L, Laakso M, Pyörälä K, Riekkinen
P. Muistivaikeuksien kokemisen yhteys persoonallisuuden piirteisiin normaaleilla vanhuksilla.
Abstraktit, Gerontologian päivät, Helsinki 30-31.12.1992: 57
2.61 Alhainen K, Sirviö J, Helkala EL, Reinikainen K, Riekkinen P. Effects of THA on the CSF
monoamine metabolites in patients with Alzheimer’s disease. 44th
American Academy of Neurology
Meeting, San Diego, 3-9.5.1992. Neurology 42, Suppl 3: 140, 1992
2.62 Koivisto K, Helkala EL, Reinikainen K, Hänninen T, Mykkänen L, Laakso M, Pyörälä K, Riekkinen
P. Prevalance of dementia in randomly selected population from East Finland. 44th
American
Academy of Neurology Meeting, San Diego, 3-9.5.1992. Neurology 42, Suppl 3: 143, 1992
2.63 Alhainen K, Helkala E-L, Reinikainen KJ, Hänninen T, Riekkinen P. The relationship of the
monoamine metabolites with clinical response to THA in Alzheimer’s disease. Third International
Conference on Alzheimer’s Disease and related Disorders, Padova. Neurobiol Aging, 13: (Suppl 1):
31-31, 1992
2.64 Ghanbari H, Miller B, Chong J, Bennette D, Azad N, Wilmer J, Risch C, Nemeroff C, Erickson K,
Reinikainen K, Koivisto K, Riekkinen P. The road to amtemortem bichemical tests for Alzheimer’s
disease.Third International Conference on Alzheimer’s Disease and related Disorders, Padova.
Neurobiol Aging, 13: (Suppl 1): 25-26, 1992
2.65 Soininen H, Reinikainen K, Partanen J, Mervaala E, Paljärvi L, Helkala E-L, Riekkinen P Sr. Slowing
of the dominant occipital rhythm in EEG is associated with low concentrations of noradrenaline in the
thalamus in patients with Alzheimer’s disease.Third International Conference on Alzheimer’s Disease
and related Disorders, Padova. Neurobiol Aging, 13: (Suppl 1): 46-47, 1992
2.66 Reinikainen KJ, Mäki-Ikola O, Heinonen E. Selegiline as a potential treatment for Alzheimer’s
disease. Neuroscience Finland 1994, Junen 17-18.6.1994, Kuopio, Finland. Kuopio University
Publications D. Medical Sciences 48, Abstracts, p 53, 1994
2.67 Reinikainen KJ. Rationale for the use of selegiline in the treatment of Alzheimer’s disease. Fourth
International Meeting on Alzheimer’s Disease and Related Disorders, 29.7-3.8.94, Minneapolis, MN,
USA. In Neurobiology of Aging, 15 (Suppl 1): s 66, 1994.
2.68 Koivisto K, Helkala E-L, Hänninen T, Vanhanen M, Kilkku O, Reinikainen K, Heinonen E, Riekkinen
PJ Sr. The effect of apolipoprotein e4 allele on clinical progression of Alzheimer’s disease.
Neurology 45 (Suppl 4), A373, 1995

_________________________________________________________________________________________
2.69 Hänninen T, Koivisto K, Reinikainen KJ, Helkala E-L, Soininen H, Mykkänen L, Laakso M,
Riekkinen Sr PJ. The prevalence of aging-associated cognitive decline (AACD) in an elderly
population. In International Symposium on Alzheimer’s Research Robinson College, Cambridge, UK,
4-7 July 1995. Alzheimer’s Research, 1 (Suppl 1) : 45 (85,P), 1995
2.70 Heino R, Mikola H, Lang H, Aaltonen H, Kilkku O, Reinikainen K, Scheinin M. Effect of
dexmedetomidine on auditory P300 and EEG. Abstract, 23rd
Congress of the Scandinavian Society of
Anesthesiologists, Reykjavik, Iceland, 1995. Acta Anesth Scand 39: Suppl 105: 174, 1995
2.71 Riekkinen PJ Sr, Koivisto K, Reinikainen KJ, Helkala E-L, Heinonen E. Rationale to treat
Alzheimer’s disease with selegiline - can we prevent the progression of the disease. Abstract, Fourth
International Nice/Springfield Symposium on Advances in Alzheimer Therapy. April 10-14, 1996,
Nice
2.72 Koivisto K, Helkala E-L, Hänninen T, Vanhanen M, ReinikainenK, Kilkku O, Heinonen E, Riekkinen
PJ Sr. Apolipoprotein e4 allele and clinical progression of Alzheimer’s disease - 3 years follow-up
study. Abstract,Fourth International Nice/Springfield Symposium on Advances in Alzheimer Therapy.
April 10-14, 1996, Nice
2.73 Koivisto K, Pirttilä T, Mehta PD, Reinikainen K, Kim KS, Kilkkku O, Heinonen E, Riekkinen PJ Sr,
Wisniewski HM. Longitudinal study of CSF amyloid proteins and ApoE in patients with probable
Alzheimer’s disease. Abstract, Fifth International Conference on Alzheimer’ s Disease and Related
Disorders, 24-29 July 1996, Osaka
2.74 Riekkinen PJ Sr, Koivisto K, Helkala E-L, Hänninen T, Reinikainen KJ, Kilkku O, Heinonen E.
Efficacy and safety of selegiline in the long-term treatment of patients with Alzheimer’s disease.
Abstract, Fifth International Conference on Alzheimer’s Disease and Related Disorders, 24-29 July
1996, Osaka
2.75 Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R, Koulu M, Mäki-Ikola O, Reinikainen
KJ, Scheinin M. Lack of interaction between concomitantly admistered selegiline and citalopram.
Abstracts of the XIIth International Symposium on Parkinson’s Disease, London, England, March 23-
26,1997. Mov Disord 12: (Suppl 1): 118, 1997
2.76 Lyytinen J, Kaakkola S, Sovijärvi A, Reinikainen K and Teräväinen H. Entacapone and
cardiorespiratory capacity during exercise in patients with Parkinson’s disease (PD). XVI World
Congress of Neurology, September 14-19, Buenos Aires, Argentina, J Neurol Sci 150 (Suppl.), 1997
2.77 Gordin A, Huupponen R, Rouru J, Korpela K, Huhtala S and Reinikainen K. Pharmacokinetics of
entacapone and catechol-O-methyltransferase (COMT) inhibition after frequent multiple dosing of
entacapone and effect on levodopa metabolism. EFNS meeting, Seville, Spain, September 19-25,
1998. Eur J Neurol 5 (Suppl 3); S165-166, 1998
2.78 Gordin A, Pentikäinen P. Mäkimartti M and Reinikainen K. Pharmacokinetics of the COMT inhibitor
entacapone in liver failure and the effect of entacapone on liver function. 50th
AAN Meeting,
Minneapolis, April 25-May2, 1998: Neurology 50 (Suppl4): A387, 1998
2.79 Rinne UK, Larsen JP, Siden Å, Worm-Petersen J, Gordin A, Leinonen M, Reinikainen K and the
Nomesafe Study Group. Long-term efficacy of entacapone in parkinsonian patients with motor
fluctuations up to 3.5 years. 5th
EFNS Congress, Copenhagen, September 2000
2.80 Rinne UK; Kieburtz K, Reinikainen K, Gordin A. Effect of Entacapone on quality of life related
assessments in Parkinson’s Disease. (6th
ICPD & MD Congress, Barcelona, 2000), Movement
Disorders 15: 135, 2000
2.81 Brooks D, Poewe W, Deuschl G, Leinonen M, Kultalahti E-R, Reinikainen K, Gordin A. Effect of
Entacapone on Activities of Daily Living and Daily Levodopa dosage in Patients with Early
Parkinson’s Disease without Motor Fluctuations. (XIV ICPD, Helsinki, 2001). Parkinsonism and
Related Disorders 7: S53, 2001

_________________________________________________________________________________________
2.82 Haapaniemi H, Reinikainen K, Leinonen M, Karonen T. Tolerability and safety of entacapone in the
treatment of parkinson’s disease. (XIV ICPD, Helsinki, 2001). Parkinsonism and Related Disorders 7:
S57, 2001
2.83 Larsen JP, Siden Å, Worm-Petersen J, Gordin A, Reinikainen K, Kultalahti E-R. Long-Term Efficacy
of Entacapone in Parkinsonian Patients with Motor Fluctuations. An Open Study of 3 years Duration.
(XIV ICPD, Helsinki, 2001). Parkinsonism and Related Disorders 7: S61, 2001
2.84 Poewe W, Deuschl G, Kultalahti E-R, Haapaniemi H, Leinonen M, Reinikainen K, Gordin A. The
Efficacy and Tolerability of Entacapone used in Combination with Controlled Release Levodopa
Preparations in Patients with Parkinson’s Disease. (XIV ICPD, Helsinki, 2001). Parkinsonism and
Related Disorders 7: S66, 2001
2.85 Reinikainen K, Karonen T, Haapaniemi H, Ahtinen H, Kaakkola S. No indication for interactions
between entacapone and antidepressants. (XIV ICPD, Helsinki, 2001). Parkinsonism and Related
Disorders 7: S67, 2001
2.86 Brooks D, Gordin A, Poewe W, Deuschl G, Leinonen M, Kultalahti E-R, Reinikainen K. Entacapone
is of benefit in patients with early Parkinson’s disease without motor fluctuations. Läknabladid – The
Icelandic Medical Journal. 43: P03, 2002
2.87 Larsen JP, Siden Å, Worm-Petresen J, Reinikainen K, Kultalahti E-R. Long-term efficacy and safety
of entacapone as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations.
Läknabladid – The Icelandic Medical Journal. 43: P14, 2002
2.88 Gordin A, Poewe, Deuschl G, Kultalahti E-R, Haapaniemi H, Leinonen M, Reinikainen K.
Entacapone as an adjunct to controlled-release levodopa preparations. Läknabladid – The Icelandic
Medical Journal. 43: P15, 2002
2.89 Reinikainen K, Leinonen M, Isojärvi J, Kaakkola S. Predicting the need for levodopa dose reduction
after entacapone initiation in PD patients with end-of-dose wearing-off (EODWO). 7th
International
Congress of Parkinson’s Disease and Movement Disorders, November 10-14, 2002, Miami, FL. Mov
Disorders 17 (Suppl 5): S45, 2002
2.90 Ahokoski O, Huupponen R, Laine K, Leinonen M, Kultalahti E-R, Reinikainen K. Entacapone
improves the bioavailability of levodopa and smoothens the plasma fluctuations of levodopa as an
adjunct to CR levodopa (Sinemet CR 25-100) after repeat dosing. 7th
International Congress of
Parkinson’s Disease and Movement Disorders, November 10-14, 2002, Miami, FL. Mov Disorders 17
(Suppl 5): S48, 2002
2.91 Myllylä V, Kaakkola S, Miettinen TE, Heikkinen H, Reinikainen K and the SIMCOM Study Group.
New triple combination of levodopa/carbidopa/entacapone is a preferred treatment in patients with
parkinson’s disease. AAN 2003, Neurology, Suppl., 2003.
2.92 Poewe W, Deuschl G, Kultalahti E-R, Reinikainen K. Entacapone is safe in long-term use in patient’s
with Parkinson’s disease. 2003 EFNS European Journal of Neurology 10 (Suppl 1), 241, 2003

_________________________________________________________________________________________
3. OTHER PAPERS
3.1 Reinikainen K: Klonatsepaamin (Rivatril) teho ja sivuvaikutukset pitkäaikaiskäytössä. Epilepsialehti
13(3), s. 4, 1981.
3.2 Reinikainen K: Pään tietokonetomografian merkitys uusilla epilepsiapotilailla. Epilepsialehti, 17(4), s.
16-17, 28-29, 1985.
3.3 Reinikainen K: Status epileptikuksen hoitoperiaatteet. Itä-Suomen Lääketiedetapahtuma 1985,
Luennot, s. 104- 105, 1985.
3.4 Reinikainen K. Muistihäiriöt ja amnestiset oireyhtymät. Itä-Suomen Lääketiedetapahtuma 1988.
3.5 Reinikainen K. Alzheimerin taudin neurokemiasta. Itä- Suomen Lääketiedetapahtuma 1990.
3.6 Reinikainen K. Löydetäänkö Alzheimerin tautiin lääkehoitoa? Lääketiede 1991. Luentolyhennelmät s.
343.
3.7 Reinikainen K. Unihäiriöiden hoidon porrastus. Itä-Suomen Lääketiedetapahtuma, s. 167, 1991
3.8 Reinikainen K. Alzheimerin taudin lääkehoidon tulavaisuuden näkymät. 4. Dementiapäivät, s. 1-5,
1994
3.9 Reinikainen K. Verenpainetaudin hoidon merkitys aivohalvauksen ehkäisyssä
27-28.10, 1995, Aivohalvauspäivät, Pori
3.10 Reinikainen K. Alzheimerin taudin lääkehoidon mahdollisuudet. Lääketiede 1996.
3.11 Reinikainen K. Eldepryl in the treatment of parkinson’s disease: A review of the efficacy and safety
with practical aspects. Luennot symposiumeissa “Eldepryl in Parkinson’s Disease” Peking, 27.9.1996
ja Shanghai, 30.9.96, Kiina.
3.12 Reinikainen K. Alzheimerin taudin lääkehoito. Pohjolan Lääketiedepäivät 1997, Oulu
3.13 Reinikainen K. Entakaponin turvallisuus lääkkeenä. Kirjassa “Entakaponi-suomalaisesta ideasta
lääkehoidoksi maailmalle”, s. 46-49, 1999, Helsinki
3.14 Reinikainen K. Parkinsonin taudin lääkehoito: Uutta ja vanhaa. Itä-Suomen Lääketiedetapahtuma,
1999, Kuopio
3.15 Reinikainen K. Optimaalinen uusi levodopa – Stalevon kehitys. Yksityislääkärilehti 2003
3.16 Reinikainen K. Imigran Radis Migreenin hoitoon. Yksityislääkärilehti 2005
3.17 Reinikainen K. Yhdistelmä voittaa monoterapian. Pros’data 2009, p7.
3.18 Reinikainen K. Voxra® – uudella tavalla vaikuttava masennuslääke. Terveyspalvelut-lehti 2010
3.19 Reinikainen K. Merkitsevää lisätietoa yhdistelmän hyödyistä. Pros’data 1/2011, p 17.
3.20 Reinikainen K. Benlysta® (belimumabi) – Uusi mahdollisuus SLE:n hoitoon. (Benlysta –New Option
to Treat SLE). Terveyspalvelut-lehti 2011
3.21 Reinikainen K. Several columns in Yksityislääkäri/Terveyspalvelut lehti 2009-2013
3.22 Reinikainen K. Editor-in-Chief of GSKs Kipu-X journal, editorials in each journal 2010-2013
3.23 Reinikainen K. Several BPH Rx related short articles in GSK’s promotional ProsData Journal 2010-
2014

Publications list of KReinikainen_01072015

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (9)

Similar to Publications list of KReinikainen_01072015

Similar to Publications list of KReinikainen_01072015 (20)

Publications list of KReinikainen_01072015